Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar<sup>®</sup>) in older patients with essential hypertension: Subgroup analysis from the Sevikar study

Cui,Zhaoqiang; Qiu,Zhaohui; Cheng,Wenli; Hu,Wei; Ma,Genshan; Cai,Xiaojun; Jin,Yafei; Zhao,Yi; He,Liqun; Li,Ying; Bu,Peili; Chen,Xiaoping; Wang,Ruxing; Chen,Lin; Dong,Peng; Feng,Liuliu; Han,Xuebin; Hong,Mei; Hou,Yinglong; Liao,Minlei; Wang,Mingliang; Wang,Xiaoyan; Xie,Jianhong; Xu,Yawei; Wang,Zhenxing; Huang,Kai; Li,Yongle; Li,Dongsheng; Ji,Xiaojun; Huang,Jing; Wang,Jun; Fang,Danhong; Wang,Jian'an; Tang,Lijiang; Liu,Yingwu; Fu,Guosheng; Du,Juan; Wang,Ling; Liu,Mengqi; Ge,Junbo

doi:10.3892/etm.2023.12338

February-2024 Volume 27 Issue 2

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

February-2024 Volume 27 Issue 2

Full Size Image

Article Open Access

Efficacy and safety of olmesartan medoxomil‑amlodipine besylate tablets (Sevikar^®) in older patients with essential hypertension: Subgroup analysis from the Sevikar study

Authors:
- Zhaoqiang Cui
- Zhaohui Qiu
- Wenli Cheng
- Wei Hu
- Genshan Ma
- Xiaojun Cai
- Yafei Jin
- Yi Zhao
- Liqun He
- Ying Li
- Peili Bu
- Xiaoping Chen
- Ruxing Wang
- Lin Chen
- Peng Dong
- Liuliu Feng
- Xuebin Han
- Mei Hong
- Yinglong Hou
- Minlei Liao
- Mingliang Wang
- Xiaoyan Wang
- Jianhong Xie
- Yawei Xu
- Zhenxing Wang
- Kai Huang
- Yongle Li
- Dongsheng Li
- Xiaojun Ji
- Jing Huang
- Jun Wang
- Danhong Fang
- Jian'an Wang
- Lijiang Tang
- Yingwu Liu
- Guosheng Fu
- Juan Du
- Ling Wang
- Mengqi Liu
- Junbo Ge
View Affiliations / Copyright

Affiliations: Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China, Department of Cardiology, Shanghai Tongren Hospital, Shanghai 200050, P.R. China, Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China, Department of Cardiology, Central Hospital of Minhang District, Shanghai 201199, P.R. China, Department of Cardiology, Zhongda Hospital Affiliated to Southeast University, Nanjing, Jiangsu 210009, P.R. China, Department of Cardiology, Jinan Central Hospital, Jinan, Shandong 250013, P.R. China, Department of Cardiology, The First Affiliated Hospital of Sun Yat‑sen University, Guangzhou, Guangdong 510062, P.R. China, Department of Cardiology, Dalian Jinzhou First People's Hospital, Dalian, Liaoning 116199, P.R. China, Department of Cardiology, Wuhan No. 1 Hospital, Wuhan, Hubei 430030, P.R. China, Department of Cardiology, Shanghai East Hospital, Shanghai 200120, P.R. China, Department of Cardiology, Qilu Hospital of Shandong University, Jinan, Shandong 250063, P.R. China, Department of Cardiology, West China Hospital of Sichuan University, Chengdu, Sichuan 610044, P.R. China, Department of Cardiology, Wuxi People's Hospital, Wuxi, Jiangsu 214023, P.R. China, Department of Cardiology, Third Affiliated Hospital of Sun Yat‑Sen University, Guangzhou, Guangdong 510630, P.R. China, Department of Cardiology, Beijing Aviation General Hospital, Beijing 100123, P.R. China, Department of Cardiology, Shidong Hospital, Shanghai 200090, P.R. China, Department of Cardiology, Shanxi Cardiovascular Hospital (Shanxi Cardiovascular Diseases Institute), Taiyuan, Shanxi 030024, P.R. China, Department of Cardiology, Second Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210003, P.R. China, Department of Cardiology, Shandong First Medical University, The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital, Jinan, Shandong, 250014, P.R. China, Department of Cardiology, Baoshan Branch, Shanghai General Hospital, Shanghai 201999, P.R. China, Department of Cardiology, Shanghai Putuo District People's Hospital, Shanghai 200060, P.R. China, Department of Cardiology, Hospital Affiliated Jiang Nan University, Wuxi, Jiangsu 214043, P.R. China, Department of Cardiology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 314408, P.R. China, Department of Cardiology, Shanghai Tenth People's Hospital, Shanghai 200072, P.R. China, Department of Cardiology, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210004, P.R. China, Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430073, P.R. China, Department of Cardiology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of Cardiology, Wuhan Third Hospital, Wuhan, Hubei 430074, P.R. China, Department of Cardiology, Wenzhou Central Hospital, Wenzhou, Zhejiang 325099, P.R. China, Department of Cardiology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, P.R. China, Department of Cardiology, Jing'an District Central Hospital of Shanghai, Shanghai 200040, P.R. China, Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang 325015, P.R. China, Department of Cardiology, The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, P.R. China, Department of Cardiology, Zhejiang Hospital, Hangzhou, Zhejiang 310013, P.R. China, Department of Cardiology, Tianjin Third Central Hospital, Tianjin 300170, P.R. China, Department of Cardiology, Sir Run Run Shaw Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310020, P.R. China, Medical Department, Daiichi Sankyo (China) Holdings Co., Ltd., Shanghai 200040, P.R. China, Department of Cardiology, Zhongshan Hospital, Fudan University, Shanghai 200032, P.R. China

Copyright: © Cui et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Article Number: 51
|
Published online on: December 5, 2023

https://doi.org/10.3892/etm.2023.12338
Expand metrics +

Abstract

Essential hypertension is a notable threat for the older (age, ≥65 years) population. However, to the best of our knowledge, a real‑world study assessing olmesartan medoxomil‑amlodipine besylate (OM‑AML) tablets in older Chinese patients with essential hypertension has not been performed. Therefore, the present study aimed to evaluate the efficacy and safety of OM‑AML tablets in these patients. A total of 463 older Chinese patients with essential hypertension treated with OM‑AML (20/5 mg) tablets (Sevikar®) were analyzed in a prospective, single‑arm, multi‑center, real‑world study. Seated systolic blood pressure (SeSBP) and seated diastolic blood pressure (SeDBP) at baseline, and at week (W)4 and W8 after OM‑AML tablet administration were measured. The mean ± standard error change of SeSBP/SeDBP was ‑10.3±0.8/‑4.6±0.5 and ‑12.5±0.8/‑5.6±0.5 mmHg at W4 and W8, respectively. At W4, 74.1 and 26.8% of patients achieved BP target according to the China and American Heart Association (AHA) criteria, while at W8, 78.0 and 38.7% of patients reached these BP targets accordingly. Finally, 76.5 and 80.5% of patients achieved BP response at W4 and W8, respectively. Furthermore, home‑measured SeSBP and SeDBP were significantly decreased from W1 to W8 (both P<0.001). Additionally, the satisfaction of both patients and physicians was elevated at W8 compared with at W0 (both P<0.001). The medication possession rate from baseline to W4 and W8 was 95.5 and 92.5%. The most common drug‑associated adverse events by system organ classes were nervous system disorder (4.5%), vascular disorder (2.8%), and general disorder and administration site conditions (2.6%), which were generally mild. In conclusion, OM‑AML tablets may be considered effective and safe in lowering BP, enabling the achievement of guideline‑recommended BP targets in older Chinese patients with essential hypertension.

View Figures

View References

1	Zhou B, Perel P, Mensah GA and Ezzati M: Global epidemiology, health burden and effective interventions for elevated blood pressure and hypertension. Nat Rev Cardiol. 18:785–802. 2021.PubMed/NCBI View Article : Google Scholar
2	Boutouyrie P, Chowienczyk P, Humphrey JD and Mitchell GF: Arterial stiffness and cardiovascular risk in hypertension. Circ Res. 128:864–886. 2021.PubMed/NCBI View Article : Google Scholar
3	Oliveros E, Patel H, Kyung S, Fugar S, Goldberg A, Madan N and Williams KA: Hypertension in older adults: Assessment, management, and challenges. Clin Cardiol. 43:99–107. 2020.PubMed/NCBI View Article : Google Scholar
4	Benetos A, Petrovic M and Strandberg T: Hypertension management in older and frail older patients. Circ Res. 124:1045–1060. 2019.PubMed/NCBI View Article : Google Scholar
5	Yasuda S, Miyamoto Y and Ogawa H: Current status of cardiovascular medicine in the aging society of Japan. Circulation. 138:965–967. 2018.PubMed/NCBI View Article : Google Scholar
6	Mohsen Ibrahim M: Hypertension in developing countries: A major challenge for the future. Curr Hypertens Rep. 20(38)2018.PubMed/NCBI View Article : Google Scholar
7	Mills KT, Stefanescu A and He J: The global epidemiology of hypertension. Nat Rev Nephrol. 16:223–237. 2020.PubMed/NCBI View Article : Google Scholar
8	Thomas NF and Dunn KS: Self-transcendence and medication adherence in older adults with hypertension. J Holist Nurs. 32:316–326. 2014.PubMed/NCBI View Article : Google Scholar
9	Lo SH, Chau JP, Woo J, Thompson DR and Choi KC: Adherence to antihypertensive medication in older adults with hypertension. J Cardiovasc Nurs. 31:296–303. 2016.PubMed/NCBI View Article : Google Scholar
10	Erdine S: Olmesartan/amlodipine: Blood pressure lowering and beyond in special populations. Ther Adv Cardiovasc Dis. 6:31–44. 2012.PubMed/NCBI View Article : Google Scholar
11	Zhang X, Zhang H, Ma Y, Che W and Hamblin MR: Management of hypertension using olmesartan alone or in combination. Cardiol Ther. 6:13–32. 2017.PubMed/NCBI View Article : Google Scholar
12	Parati G, Kjeldsen S, Coca A, Cushman WC and Wang J: Adherence to Single-Pill versus free-equivalent combination therapy in hypertension: A systematic review and meta-analysis. Hypertension. 77:692–705. 2021.PubMed/NCBI View Article : Google Scholar
13	Al-Makki A, DiPette D, Whelton PK, Murad MH, Mustafa RA, Acharya S, Beheiry HM, Champagne B, Connell K, Cooney MT, et al: Hypertension pharmacological treatment in adults: A World Health organization guideline executive summary. Hypertension. 79:293–301. 2022.PubMed/NCBI View Article : Google Scholar
14	Bakris G, Ali W and Parati G: ACC/AHA Versus ESC/ESH on hypertension guidelines: JACC guideline comparison. J Am Coll Cardiol. 73:3018–3026. 2019.PubMed/NCBI View Article : Google Scholar
15	Derosa G, Mugellini A, Pesce RM, D'Angelo A and Maffioli P: Olmesartan combined with amlodipine on oxidative stress parameters in type 2 diabetics, compared with single therapies: A randomized, controlled, clinical trial. Medicine (Baltimore). 95(e3084)2016.PubMed/NCBI View Article : Google Scholar
16	Chrysant SG, Melino M, Karki S, Lee J and Heyrman R: The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study. Clin Ther. 30:587–604. 2008.PubMed/NCBI View Article : Google Scholar
17	Volpe M, Brommer P, Haag U and Miele C: Efficacy and tolerability of olmesartan medoxomil combined with amlodipine in patients with moderate to severe hypertension after amlodipine monotherapy: A randomized, double-blind, parallel-group, multicentre study. Clin Drug Investig. 29:11–25. 2009.PubMed/NCBI View Article : Google Scholar
18	Levi M, Pasqua A, Cricelli I, Cricelli C, Piccinni C, Parretti D and Lapi F: Patient adherence to olmesartan/amlodipine combinations: Fixed versus extemporaneous combinations. J Manag Care Spec Pharm. 22:255–262. 2016.PubMed/NCBI View Article : Google Scholar
19	Lucas C, Romatet S, Mekiès C, Allaf B and Lantéri-Minet M: Stability, responsiveness, and reproducibility of a visual analog scale for treatment satisfaction in migraine. Headache. 52:1005–1018. 2012.PubMed/NCBI View Article : Google Scholar
20	Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, et al: 2017 ACC/AHA/AA PA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the american college of Cardiology/American heart association task force on clinical practice guidelines. Hypertension. 71:e13–e115. 2018.PubMed/NCBI View Article : Google Scholar
21	Wu S, Xu Y, Zheng R, Lu J, Li M, Chen L, Huo Y, Xu M, Wang T, Zhao Z, et al: Hypertension Defined by 2017 ACC/AHA guideline, ideal cardiovascular health metrics, and risk of cardiovascular disease: A nationwide prospective cohort study. Lancet Reg Health West Pac. 20(100350)2022.PubMed/NCBI View Article : Google Scholar
22	Chrysant SG, Lee J, Melino M, Karki S and Heyrman R: Efficacy and tolerability of amlodipine plus olmesartan medoxomil in patients with difficult-to-treat hypertension. J Hum Hypertens. 24:730–738. 2010.PubMed/NCBI View Article : Google Scholar
23	Oparil S, Lee J, Karki S and Melino M: Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: Evaluation by baseline hypertension stage and prior antihypertensive medication use. J Cardiovasc Pharmacol. 54:427–436. 2009.PubMed/NCBI View Article : Google Scholar
24	Weir MR, Shojaee A and Maa JF: Efficacy of amlodipine/olmesartan medoxomil +/- hydrochlorothiazide in patients aged >/=65 or <65 years with uncontrolled hypertension on prior monotherapy. Postgrad Med. 125:124–134. 2013.PubMed/NCBI View Article : Google Scholar
25	Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H and Arakawa K: OlmeSartan and Calcium Antagonists Randomized (OSCAR) Study Group. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med. 125:981–990. 2012.PubMed/NCBI View Article : Google Scholar
26	Ding S, Liu J, Fu Q and Zheng Y: Clinical effects of combined olmesartan medoxomil and amlodipine on clinic and ambulatory blood pressure in elderly patients with resistant hypertension. Arch Gerontol Geriatr. 57:423–427. 2013.PubMed/NCBI View Article : Google Scholar
27	Kreutz R, Ammentorp B, Laeis P and de la Sierra A: Efficacy and tolerability of triple-combination therapy with olmesartan, amlodipine, and hydrochlorothiazide: A subgroup analysis of patients stratified by hypertension severity, age, sex, and obesity. J Clin Hypertens (Greenwich). 16:729–740. 2014.PubMed/NCBI View Article : Google Scholar
28	Zhu JR, Zhang SY and Gao PJ: Efficacy and safety of olmesartan medoxomil/amlodipine fixed-dose combination for hypertensive patients uncontrolled with monotherapy. Arch Pharm Res. 37:1588–1598. 2014.PubMed/NCBI View Article : Google Scholar
29	Sohn IS, Ihm SH, Kim GH, Park SM, Hong BK, Lee CH, Lee SH, Chang DI, Joo SP, Lee SC, et al: Real-world evidence on the strategy of olmesartan-based triple single-pill combination in Korean hypertensive patients: A prospective, multicenter, observational study (RESOLVE-PRO). Clin Hypertens. 27(21)2021.PubMed/NCBI View Article : Google Scholar

Journals